文献速递肝胆胰外科

IA期胰腺癌根治性切除的长期肿瘤学结局与预后因素

Long-term oncologic outcomes and prognostic factors in resected stage IA pancreatic cancer: a retrospective cohort study.
PubMed 文献 · Surg Endosc · 2026-03-04

该回顾性队列研究分析了2005-2022年间102例IA期胰腺导管腺癌根治性切除患者,其中48例(47.1%)接受微创手术,78例(76.5%)接受辅助化疗。5年总生存率和无病生存率分别为58.2%和48.6%。多因素分析显示年龄、女性和辅助化疗与总生存独立相关,但辅助化疗对左侧肿瘤无总生存获益。

要点

  • IA期PDAC根治性切除后5年OS为58.2%,DFS为48.6%。
  • 辅助化疗与改善总生存独立相关(HR 0.24,p=0.001)。
  • 辅助化疗对左侧肿瘤未显示总生存获益,需进一步研究。

核心结论

  • 辅助化疗与IA期胰腺导管腺癌根治性切除后总体改善结局相关,但在左侧肿瘤中未带来总生存获益。

研究设计与样本

  • 回顾性队列研究,纳入2005-2022年Severance医院102例组织学确诊IA期PDAC接受根治性PD或DP的患者,排除新辅助治疗或其他术式者。

主要发现

  • 102例中48例(47.1%)接受微创手术,78例(76.5%)接受辅助化疗;平均肿瘤大小1.62 cm;右侧肿瘤49例,左侧53例。
  • 微创手术在DP组比PD组更常见(67.9% vs. 24.5%,p<0.001)。
  • 12例(11.8%)最终病理切缘阳性;59例(57.8%)发生术后并发症。
  • 5年总生存率和无病生存率分别为58.2%和48.6%。
  • 多因素分析:年龄(HR 1.05,p=0.027)、女性(HR 0.32,p=0.006)和辅助化疗(HR 0.24,p=0.001)与总生存独立相关;年龄和辅助化疗也与无复发生存独立相关。

临床怎么用

  • 对于IA期PDAC根治性切除患者,可考虑辅助化疗以改善生存,但左侧肿瘤患者需个体化评估。

局限性

  • 回顾性单中心研究,样本量有限(102例),辅助化疗在左侧肿瘤中的获益需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stage IA pancreatic ductal adenocarcinoma (PDAC) is an early-stage disease where curative resection is feasible. While minimally invasive surgery (MIS) is increasingly used and adjuvant chemotherapy is standard for resected PDAC, their roles in stage IA patients remain unclear. This study evaluated the oncologic and perioperative outcomes of surgical approach and adjuvant chemotherapy in stage IA PDAC patients. METHODS: We retrospectively analyzed patients with histologically confirmed stage IA PDAC who underwent curative-intent pancreaticoduodenectomy (PD) or distal pancreatectomy (DP) at Severance Hospital (2005-2022). Those receiving neoadjuvant therapy or other procedures were excluded. Survival was assessed with Kaplan-Meier estimates and Cox models. RESULTS: Among 102 patients, 48 (47.1%) underwent MIS and 78 (76.5%) received adjuvant chemotherapy. The mean tumor size was 1.62 cm; 49 patients had right-sided tumors and 53 had left-sided tumors. MIS was more common in the DP group than the PD group (67.9 vs. 24.5%, p < 0.001). 12 patients (11.8%) had pathologic margin involvement of the tumor in final pathology. 59 patients (57.8%) experienced complications postoperatively and 78 patients (76.5%) received adjuvant chemotherapy. The 5-year overall and disease-free survival rates were 58.2% and 48.6%, respectively. On multivariable analysis, age (HR 1.05, p = 0.027), female sex (HR 0.32, p = 0.006), and adjuvant chemotherapy (HR 0.24, p = 0.001) were independently associated with overall survival. Age and adjuvant chemotherapy were also independently associated with recurrence-free survival. CONCLUSION: Adjuvant chemotherapy was associated with improved outcomes in stage IA PDAC overall, but did not confer an overall survival benefit in left-sided tumors, underscoring the need for larger studies to define its role in this subgroup.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Cho IS, Hwang HK, Kim SH, et al. Long-term oncologic outcomes and prognostic factors in resected stage IA pancreatic cancer: a retrospective cohort study. Surg Endosc. 2026. PMID: 41781776. doi:10.1007/s00464-026-12646-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。